Itoh H, Pratt R E, Dzau V J
Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts.
J Clin Invest. 1990 Nov;86(5):1690-7. doi: 10.1172/JCI114893.
Vascular remodeling is central to the pathophysiology of hypertension and atherosclerosis. Recent evidence suggests that vasoconstrictive substances, such as angiotensin II (AII), may function as a vascular smooth muscle growth promoting substance. To explore the role of the counterregulatory hormone, atrial natriuretic polypeptide (ANP) in this process, we examined the effect of ANP (alpha-rat ANP [1-28]) on the growth characteristics of cultured rat aortic smooth muscle (RASM) cells. ANP (10(-7) M) significantly suppressed the proliferative effect of 1% and 5% serum as measured by 3H-thymidine incorporation and cell number, confirming ANP as an antimitogenic factor. In quiescent RASM cells, ANP (10(-7), 10(-6) M) significantly suppressed the basal incorporations of 3H-uridine and leucine by 50 and 30%, respectively. ANP (10(-7), 10(-6) M) also suppressed AII-induced RNA and protein syntheses (by 30-40%) with the concomitant reduction of the cell size. Furthermore, ANP also significantly attenuated the increase of 3H-uridine and leucine incorporations caused by transforming growth factor-beta (4 x 10(-11), 4 x 10(-10) M), a potent hypertrophic factor. These results indicate that ANP possesses an antihypertrophic action on vascular smooth muscle cells. Down-regulation of protein kinase C by 24-h treatment with phorbol 12,13-dibutyrate did not inhibit ANP-induced suppression on 3H-uridine incorporation. Based on the observation that ANP was more potent than a ring-deleted analogue of ANP on inhibiting 3H-uridine incorporation, we conclude that the ANP's inhibitory effect is primarily mediated via the activation of a guanylate cyclase-linked ANP receptor(s). Indeed 8-bromo cGMP mimicked the antihypertrophic action of ANP. Accordingly, we speculate that in addition to its vasorelaxant and natriuretic effects, the antihypertrophic action of ANP observed in the present study may serve as an additional compensatory mechanism of ANP in hypertension.
血管重塑是高血压和动脉粥样硬化病理生理学的核心。最近的证据表明,血管收缩物质,如血管紧张素II(AII),可能作为一种促进血管平滑肌生长的物质发挥作用。为了探讨反调节激素心房利钠多肽(ANP)在此过程中的作用,我们研究了ANP(α-大鼠ANP [1-28])对培养的大鼠主动脉平滑肌(RASM)细胞生长特性的影响。通过3H-胸苷掺入和细胞数量测定,ANP(10^(-7) M)显著抑制了1%和5%血清的增殖作用,证实ANP是一种抗有丝分裂因子。在静止的RASM细胞中,ANP(10^(-7)、10^(-6) M)分别使3H-尿苷和亮氨酸的基础掺入量显著降低50%和30%。ANP(10^(-7)、10^(-6) M)还抑制了AII诱导的RNA和蛋白质合成(降低30 - 40%),同时细胞大小减小。此外,ANP还显著减弱了转化生长因子-β(4×10^(-11)、4×10^(-10) M)(一种强效的肥大因子)引起的3H-尿苷和亮氨酸掺入增加。这些结果表明,ANP对血管平滑肌细胞具有抗肥大作用。用佛波醇12,13 - 二丁酸酯处理24小时使蛋白激酶C下调,并不抑制ANP诱导的对3H-尿苷掺入的抑制作用。基于ANP在抑制3H-尿苷掺入方面比ANP的环缺失类似物更有效的观察结果,我们得出结论,ANP的抑制作用主要通过鸟苷酸环化酶连接的ANP受体激活介导。实际上,8 - 溴环鸟苷酸模拟了ANP的抗肥大作用。因此,我们推测,除了其血管舒张和利钠作用外,本研究中观察到的ANP的抗肥大作用可能是ANP在高血压中的一种额外的代偿机制。